Schott Pharma

Last updated
Schott Pharma AG & Co. KGaA
Company type KGaA with Aktiengesellschaft as partner with unlimited liability
FWB:  1SXP
MDAX
ISIN DE000A3ENQ51
Industry Healthcare
FoundedAugust 1, 2022;3 years ago (2022-08-01)
Headquarters Mainz, Germany
Key people
Andreas Reisse, CEO
Reinhard Mayer, CFO
ProductsPharmaceutical drug containment and delivery systems
RevenueIncrease2.svg €986 million (2024/2025) [1]
Owner Schott AG
Number of employees
4,811 (as of September 30, 2025) [1]
Divisions
  • Drug Containment Solutions
  • Drug Delivery Systems
Website schott-pharma.com

Schott Pharma (stylized as SCHOTT Pharma) is a provider of drug containment solutions and delivery systems for injectable drugs. [2] [3] Originally a division of glass manufacturer Schott AG, the company went public on the Frankfurt Stock Exchange in 2023. [4] Headquartered in Mainz, Germany, [5] [6] the company operates in 14 countries. [7]

Contents

History

Filling Schott glass ampoules with medications (1932) Abfullautomat 1932 SCHOTT.jpg
Filling Schott glass ampoules with medications (1932)
Schott & Gen. advertisement for borosilicate glass vials (1923) Druckschrift Fiolenkorper 1923 SCHOTT.jpg
Schott & Gen. advertisement for borosilicate glass vials (1923)

In 1887, Otto Schott developed borosilicate glass, a form of glassware used to reagent bottles and flasks. From 1911, Schott manufactured borosilicate glass tubing for the production of pharmaceutical ampoules and vials. [8]

Schott Pharma was established as a standalone company in 2022 under the name Schott Pharma AG & Co. KGaA [9] [6] through an equity carve-out (or spin-off) from Schott AG, a manufacturer of specialty glass and glass-ceramics. [10] [11] In the same year, the company announced their plans to present an IPO, but this was reportedly postponed to 2023 due to the Russian invasion of Ukraine. [5]

In June 2023, Schott Pharma announced plans to hold the IPO in September 2023. [12] This plan was enacted in September, with Schott Pharma going public on the Frankfurt Stock Exchange. [13] The IPO was initially priced at 27€ per share, [14] [15] and a potential valuation of up to 4.1 billion euros, [16] but increased the share price to 30€ the following day. [17] [13] The IPO was the largest of the year in Germany. [18] [19] In December 2023, Schott Pharma was included in the SDAX. [20] In September 2024, Schott Pharma was promoted to the MDAX. [21]

Production & Manufacturing

The company is headquartered in Mainz and operates in 16 locations across 14 countries. [22]

Europe

North America

South America

Asia

Products

Schott Pharma develops and manufactures drug containment solutions and delivery systems for injectable drugs, which it supplies to companies in the biotechnology and pharmaceutical industries. [31]

Its business is divided into two divisions:

Governance

Schott Pharma is a subsidiary of SCHOTT AG, which holds controlling shares (as of 2023: 77%). [19] [17] SCHOTT AG is owned by the Carl Zeiss Foundation. [25]

Schott Pharma is listed on the Frankfurt Stock Exchange's MDAX. [21]

Independent Supervisory Board

The Supervisory Board for the Schott Pharma AG is as follows: [34] [35]

Financial Results

2022/23 [37] 2023/24 [37] 2024/25 [1]
Revenue in €m899957986
Employees4,6464,6904,811

References

  1. 1 2 3 SCHOTT Pharma Annual Report 2025 (accessed December 11, 2025)
  2. ↑ Kansteiner, Fraiser (2023-12-23). "Glass specialist Schott Pharma touts 2023 sales growth, Serbia expansion and hiring plans". Fierce Pharma. Retrieved 2024-04-08.
  3. ↑ "EQS-News: SCHOTT Pharma bestätigt Prognose für das Geschäftsjahr 2024 anlässlich seiner Q2-Ergebnisse; Geschäftsjahr 2025 durch geringeres Wachstum bei Spritzen beeinflusst" [EQS-News: SCHOTT Pharma confirms forecast for the 2024 financial year on the occasion of its Q2 results; financial year 2025 influenced by lower growth in syringes]. 4Investors.de (in German). 2024-05-14. Retrieved 2024-06-24.
  4. ↑ Rauffmann, Theresa (2024-06-27). "Abhängigkeit vom Geschäft mit Diätspritzen wird zum Problem" [Dependence on the business with diet syringes becomes a problem]. www.handelsblatt.com. Retrieved 2024-09-18.
  5. 1 2 Ibrahim, Samir (2023-09-28). "Schott Pharma startet erfolgreich an der Frankfurter Börse". tagesschau.de (in German). Retrieved 2024-06-24.
  6. 1 2 3 Nünchert, Ike (2022-08-03). "SCHOTT Pharma: Carve-Out für ein mögliches IPO" [SCHOTT Pharma: Carve-Out for a possible IPO]. Going Public. Retrieved 2024-06-24.
  7. ↑ "Größter Börsengang in 2023: So hat sich die SCHOTT Pharma-Aktie seit ihrem IPO entwickelt - und so könnte es in 2024 nun weitergehen". finanzen.net. 2024-01-24. Retrieved 2024-02-28.
  8. ↑ "Impfstoff-Ampullen – Rohrglas für Lebensretter - VBG Spezial". glaskeramik.org. VBG. 2021-07-04. Retrieved 2024-02-28.
  9. ↑ Dunleavy, Kevin (2023-09-06). "After one year as standalone business, glassmaker Schott Pharma sets course for IPO". Fierce Pharma. Retrieved 2024-06-24.
  10. ↑ Kansteiner, Fraiser (2022-01-08). "Glass maker Schott's pharma business sets out on its own. Will an IPO follow?". Fierce Pharma. Retrieved 2024-02-28.
  11. ↑ Landsteiner, Fraiser (2022-08-01). "Glass maker Schott's pharma business sets out on its own. Will an IPO follow?". Fierce Pharma. Retrieved 2024-06-24.
  12. ↑ Wilkes, William; Gopinath, Swetha (2023-06-22). "Schott to Hold IPO of Medical Glassware Unit in September: Bloomberg.com". Bloomberg.com: N.PAG–N.PAG.
  13. 1 2 "Schott Pharma trades up following biggest German IPO since Porsche: Global Capital". Global Capital: N.PAG–N.PAG. 2023-10-16.
  14. ↑ Gopinath, Swetha (2023-09-28). "Germany's Schott Raises €813 Million in IPO of Medical-Glass Arm". www.bloomberg.com. Retrieved 2024-06-24.
  15. ↑ gsp (2023-09-29). "Schott Pharma geht mit Freshfields an die Frankfurter Börse" [Schott Pharma goes to the Frankfurt Stock Exchange with Freshfields]. Extrajournal.Net (in German). Retrieved 2024-06-24.
  16. ↑ "Schott Pharma prices IPO at 27 euros per share". Reuters. 2023-09-27. Retrieved 2024-06-24.
  17. 1 2 "SCHOTT Pharma feiert erfolgreiches Börsendebüt: Erstkurs über Ausgabepreis" [SCHOTT Pharma celebrates successful stock market debut: First price on issue price]. Finanzen Net (in German). 2023-09-28. Retrieved 2024-06-24.
  18. ↑ Farr, Emma-Victoria; Mayo Cerqueiro, Pablo (2023-09-28). "Schott Pharma shares jump 16% in Frankfurt trading debut". reuters.com. Reuters. Retrieved 2024-02-28.
  19. 1 2 "Schott Pharma startet erfolgreich an der Börse". tagesschau.de. 2023-09-28. Retrieved 2024-02-28.
  20. ↑ Ingerl, Christian (2023-12-13). "Profitabler Small Cap: Zulieferer Schott Pharma bald im SDax". Capital. Retrieved 2024-02-28.
  21. 1 2 Ruhkamp, Christoph (2024-10-04). "Finanzchefin bringt Schott Pharma in den MDax" [Chief Financial Officer brings Schott Pharma into the MDax]. boersen-zeitung.de (in German). Retrieved 2024-11-04.
  22. ↑ "Größter Börsengang in 2023: So hat sich die SCHOTT Pharma-Aktie seit ihrem IPO entwickelt - und so könnte es in 2024 nun weitergehen". finanzen.net. 2024-01-24. Retrieved 2024-02-28.
  23. ↑ Zeitung, Badische (2022-12-02). "SCHOTT Pharma: Ein globales Kompetenzzentrum in Müllheim". Badische Zeitung (in German). Retrieved 2024-06-24.
  24. ↑ Schlegel, Marion (2023-12-19). "SDAX-Neuling Schott Pharma gibt ordentlich Gas: Zahlen kommen gut an". www.deraktionaer.de (in German). Retrieved 2024-06-24.
  25. 1 2 3 "SCHOTT Pharma baut Produktion in China und Ungarn aus – ZWP online – das Nachrichtenportal für die Dentalbranche". www.zwp-online.info (in German). 2022-09-22. Retrieved 2024-06-24.
  26. 1 2 "SCHOTT: solides Ergebnis trotz konjunktureller Herausforderungen – ZWP online – das Nachrichtenportal für die Dentalbranche" [SCHOTT: solid result despite economic challenges]. www.zwp-online.info (in German). 2024-02-12. Retrieved 2024-06-24.
  27. 1 2 Herpai, Gergely (2024-07-12). "Schott Pharma's HUF 28 bln Investment Boosts Hungarian Pharmaceutical Manufacturing: Budapest Business Journal". Budapest Business Journal. 32 (14): 8–8.
  28. ↑ "Schott Pharma Begins Construction on Serbia Plant: American Ceramic Society Bulletin". American Ceramic Society Bulletin. 103 (5): 49–49. July 2024.
  29. 1 2 Schott (2024-03-18). "SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility in Wilson, North Carolina: Business Wire (English)". Business Wire (English).
  30. ↑ Anselmo, Joelle (2024-03-27). "Schott Pharma to build $371M syringe factory: Construction Dive". Construction Dive: N.PAG–N.PAG.
  31. ↑ SCHOTT Pharma Annual Report 2022/2023, SCHOTT Pharma, p. 14, retrieved 2024-02-28
  32. ↑ Kaiser, Lea (2023-10-24). "Next generation pharma glass: SCHOTT AG launches FIOLAX® Pro Glass tubing". BusinessWire. Retrieved 2024-06-24.
  33. ↑ "Schott Pharma rolls out pre-filled polymer syringes for deep-cold medication". NS Medical Devices. 2023-05-18. Retrieved 2024-02-28.
  34. ↑ Mills, Jess (2023-05-02). "Schott appoints Supervisory Board of Schott Pharma". Glass International. Retrieved 2024-06-24.
  35. ↑ "SCHOTT bestellt Aufsichtsrat der SCHOTT Pharma AG" [SCHOTT appoints Supervisory Board of SCHOTT Pharma AG]. ZWP-online. 2023-05-02. Retrieved 2024-06-24.
  36. ↑ "SCHOTT Pharma with successful Annual General Meeting: Shareholders approve all agenda items". schott-pharma.com. Retrieved 21 October 2025.
  37. 1 2 "SCHOTT Pharma Annual Report 2023/2024" (PDF). schott.com. Retrieved 15 January 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.